Alpelisib, a PI3Kα specific inhibitor, in combination with fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously [8]. This evidence concerns the gene ERBB2 and breast carcinoma.